Your Flagship Event Driving ADC Innovation, Insights & Connections

Pfizer pens $10B, 12-drug deal with Innovent in broad bet on Chinese cancer med innovation
Iza-Bren Is Approved in China for Recurrent/Metastatic Nasopharyngeal Carcinoma
Novartis to acquire Myricx Bio for up to $1.5B, adding cancer-fighting ADC payload platform
Daiichi, AstraZeneca’s Enhertu breaks into early breast cancer with dual FDA approvals
Gilead’s Trodelvy nabs broad FDA approval in front-line TNBC, fueling TROP2 ADC market war
J&J makes $1B upfront bet on emerging DAC space by netting Firefly Bio

Predicting, Characterizing & Mitigating ADC Toxicities to Widen Therapeutic Index

Predicting, Characterizing & Mitigating ADC Toxicities to Widen Therapeutic Index

9:20 am - Monday 12th October 2026

Speakers:

Rakesh Dixit

Rakesh Dixit

President & Chief Executive Officer

Bionavigen Oncology